Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC
To evaluate the efficacy and safety of trilaciclib combined with standard treatment project as an adjuvant treatment for Head and neck cancer after surgery
Head and Neck Cancer Squamous Cell Carcinoma
DRUG: Trilaciclib + Cisplatin
Incidence of Grade 3/4 Neutropenia, Neutrophils ≤ 1.0\*109/L, From the date of enrollment to the 15th day after the completion of postoperative concurrent chemoradiotherapy.
Incidence of Grade 3/4 Thrombocytopenia during Chemotherapy, Platelets≤ 50\*109/L, From the date of enrollment to the 15th day after the completion of postoperative concurrent chemoradiotherapy.|Incidence of Grade 3/4 Anemia during Chemotherapy, hemoglobin\<80g/L, From the date of enrollment to the 15th day after the completion of postoperative concurrent chemoradiotherapy.|Incidence of Febrile Neutropenia, ANC \<0.5×10\^9/L or ANC between 0.5 and 1×10\^9/L (Grade 3) but expected to drop to \<0.5×10\^9/L within the next 48 hours;temperature ≥38.3°C or ≥38.0°C for more than 1 hour., From the date of enrollment to the 15th day after the completion of postoperative concurrent chemoradiotherapy.|Incidence of Platelet Transfusion, Incidence of Platelet Transfusion, From the date of enrollment to the 15th day after the completion of postoperative concurrent chemoradiotherapy.|Incidence of Red Blood Cell Transfusion, Incidence of Red Blood Cell Transfusion, From the date of enrollment to the 15th day after the completion of postoperative concurrent chemoradiotherapy.
Survival Data-Related Endpoints, 1-Year Disease-Free Survival (DFS) Rate, 1-Year
Trilaciclib indication: Trilaciclib, a CDK4/6 inhibitor, was used before chemotherapy to reduce the incidence of bone marrow suppression and approved by the FDA for small cell lung cancer patients in 2021.